List view / Grid view
11 November 2022 | By Catherine Eckford (European Pharmaceutical Review)
EPR rounds up results from several key clinical trials on therapies for hypertension and heart failure presented at the American Heart Association’s Scientific Sessions 2022.
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
24 May 2017 | By Niamh Marriott, Junior Editor
A novel tablet is helping heart failure patients to manage their disease including drug dosages, according to new research...
27 July 2023 | By Dr Ibon Garitaonandia (CellProthera)
Cell-based therapies have the potential to regenerate heart tissue as an alternative to heart transplants. Here, Dr Ibon Garitaonandia, Chief Scientific Officer at CellProthera, shares how CD34+ cells are demonstrating promising results in clinical studies.
28 February 2023 | By Catherine Eckford (European Pharmaceutical Review)
In a Phase III trial, a new cell therapy has shown potential for the first time to treat inflammation, a major contributor to heart failure.
28 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers assess aspirin as a preventive measure for patients who have both diabetes and heart failure...
11 August 2014 | By Novartis
New data revealing the reduction in cardiovascular deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress...
23 May 2014 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion for the use of RLX030 in the treatment of acute heart failure...
13 November 2018 | By European Pharmaceutical Review
Yale-led research has shown how sacubitril-valsartan improves markers of poor prognosis in individuals who are hospitalised with acute heart failure...
4 May 2016 | By Victoria White, Digital Content Producer
The heart failure treatment market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, according to research and consulting firm GlobalData.
4 March 2022 | By European Pharmaceutical Review
Phase III trial shows that adults hospitalised for acute heart failure were 36 percent more likely to experience a clinical benefit if initiated on empagliflozin.
26 November 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces the appointment of its three Co-Principal Investigators for the CHART-2 study (Congestive Heart Failure cArdiopoietic Regenerative Therapy), authorized in the United States by the FDA in January, and anticipated to start by the end of 2014...
19 November 2019 | By Rachael Harper (European Pharmaceutical Review)
A study evaluating the efficacy and safety of vericiguat, a treatment for patients with worsening chronic heart failure, has met the primary efficacy endpoint.
10 April 2013 | By European Pharmaceutical Review
Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in partnership with BG Medicine, Inc., (NASDAQ: BGMD) to run on Abbott’s ARCHITECT immunochemistry platform.
31 August 2021 | By Anna Begley (European Pharmaceutical Review)
Jardiance displayed a 21 percent risk reduction in adults with heart failure with preserved ejection fraction in Phase III study.
